Dexamethasone and Diquafosol tetrasodium

The combination of dexamethasone and diquafosol tetrasodium appears to be a therapeutic approach for treating dry eye conditions, particularly after procedures like femtosecond laser-assisted in situ keratomileusis (FS-LASIK). Dexamethasone is a corticosteroid that prevents inflammation by inhibiting the release of substances in the body that cause inflammation[8]. It's used to treat various inflammatory conditions including those affecting the eyes[9]. Diquafosol tetrasodium is a P2Y2 receptor agonist that acts on goblet cells, corneal and conjunctival epithelium, and meibomian glands to promote tear fluid, mucin, and lipid secretion, helping with epithelium repair[1]. It has been shown to reduce corneal and conjunctival staining, prolong tear breakup time, increase Schirmer test scores, and improve subjective symptoms in patients with dry eye[1][7]. Clinical studies have demonstrated that diquafosol tetrasodium, either alone or in combination with other agents like sodium hyaluronate, can significantly improve both subjective symptoms and objective signs of dry eye[1][3][4]. The combination therapy has shown potential to promote corneal nerve growth in patients after FS-LASIK[1]. Additionally, diquafosol treatment has been found to reduce intracellular reactive oxygen species (ROS) levels, apoptosis, and inflammation in dry eye models[5]. While the search results don't specifically mention a fixed combination product of dexamethasone and diquafosol tetrasodium, they do suggest that these agents might be used together in treating ocular surface conditions, particularly inflammatory dry eye conditions.